Related Experiment Videos
[Interferon beta 1-a in multiple sclerosis: 1-year experience in 62 patients]
C P Tilbery1, E Felipe, M A Moreira
1Centro de Atendimento e Tratamento da Esclerose Múltipla, Clínica Neurológica, Departamento de Medicina, Santa Casa de São Paulo, Brazil. neurologia@santacasasp.org.br
Arquivos De Neuro-Psiquiatria
|August 2, 2000
Summary
Interferon beta 1-a significantly reduced relapse rates and disease progression in patients with relapsing-remitting multiple sclerosis. This treatment was well-tolerated, with 85% completing a year of therapy.
Area of Science:
- Neuroimmunology
- Clinical Neurology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Relapsing-remitting MS (RRMS) is the most common form, characterized by distinct attacks and remissions.
- Effective disease-modifying therapies are crucial for managing RRMS.
Purpose of the Study:
- To evaluate the efficacy and tolerability of interferon beta 1-a in ambulatory patients with RRMS.
- To assess the impact of interferon beta 1-a on exacerbation rates and disease progression.
Main Methods:
- A clinical trial involving 62 ambulatory RRMS patients with an Expanded Disability Status Scale (EDSS) of 0 to 5.5.
- Patients received subcutaneous injections of 3 million international units of interferon beta 1-a three times weekly.
- Outcomes measured included annual exacerbation rate and changes in EDSS score over 1 year.
Main Results:
- The annual exacerbation rate was 0.63 in the interferon beta 1-a group, compared to 1.32 in the untreated group.
- The mean EDSS score decreased to 2.0 in treated patients, versus 4.7 in untreated patients.
- Interferon beta 1-a demonstrated good tolerability, with 85% of patients completing the 1-year treatment duration.
Conclusions:
- Interferon beta 1-a is an effective treatment for reducing exacerbations and slowing disease progression in RRMS.
- The therapy is well-tolerated, supporting its use in managing ambulatory patients with RRMS.
- Subcutaneous interferon beta 1-a offers a viable therapeutic option for improving outcomes in multiple sclerosis.